APA (7th ed.) Citation

Koch, R., Gelderblom, H., Haveman, L., Brichard, B., Jürgens, H., Cyprova, S., . . . Dirksen, U. (2022). High-dose treosulfan and melphalan as consolidation therapy versus standard therapy for high-risk (metastatic) ewing sarcoma. Journal of clinical oncology, 40(21), . https://doi.org/10.1200/JCO.21.01942

Chicago Style (17th ed.) Citation

Koch, Raphael, et al. "High-dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-risk (metastatic) Ewing Sarcoma." Journal of Clinical Oncology 40, no. 21 (2022). https://doi.org/10.1200/JCO.21.01942.

MLA (9th ed.) Citation

Koch, Raphael, et al. "High-dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-risk (metastatic) Ewing Sarcoma." Journal of Clinical Oncology, vol. 40, no. 21, 2022, https://doi.org/10.1200/JCO.21.01942.